Axillary Hyperhidrosis

Brickell Biotech Inc (NASDAQ: BBI) has announced that the final patient completed the Phase 3 Cardigan I study, and all planned patients have been enrolled in the Phase 3 Cardigan II study.  Both studies evaluate sofpironium bromide gel, 15% in patients with primary axillary (...

Fortress Biotech Inc's (NASDAQ: FBIO) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc, a wholly-owned subsidiary of Eli Lilly And Co (NYSE: LLY). The transaction is...